• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于人群的癌症生存分析中治愈分数的估计与建模。

Estimating and modeling the cure fraction in population-based cancer survival analysis.

作者信息

Lambert Paul C, Thompson John R, Weston Claire L, Dickman Paul W

机构信息

Department of Health Sciences, Centre for Biostatistics and Genetic Epidemiology, University of Leicester, 22-28 Princess Road West, Leicester LE1 6TP, UK.

出版信息

Biostatistics. 2007 Jul;8(3):576-94. doi: 10.1093/biostatistics/kxl030. Epub 2006 Oct 4.

DOI:10.1093/biostatistics/kxl030
PMID:17021277
Abstract

In population-based cancer studies, cure is said to occur when the mortality (hazard) rate in the diseased group of individuals returns to the same level as that expected in the general population. The cure fraction (the proportion of patients cured of disease) is of interest to patients and is a useful measure to monitor trends in survival of curable disease. There are 2 main types of cure fraction model, the mixture cure fraction model and the non-mixture cure fraction model, with most previous work concentrating on the mixture cure fraction model. In this paper, we extend the parametric non-mixture cure fraction model to incorporate background mortality, thus providing estimates of the cure fraction in population-based cancer studies. We compare the estimates of relative survival and the cure fraction between the 2 types of model and also investigate the importance of modeling the ancillary parameters in the selected parametric distribution for both types of model.

摘要

在基于人群的癌症研究中,当患病个体组的死亡率(风险率)恢复到与一般人群预期水平相同时,就认为实现了治愈。治愈比例(治愈疾病的患者比例)是患者关注的焦点,也是监测可治愈疾病生存趋势的一项有用指标。治愈比例模型主要有两种类型,即混合治愈比例模型和非混合治愈比例模型,以往的大多数研究都集中在混合治愈比例模型上。在本文中,我们扩展了参数化非混合治愈比例模型,以纳入背景死亡率,从而在基于人群的癌症研究中提供治愈比例的估计值。我们比较了这两种模型类型下相对生存率和治愈比例的估计值,并研究了在所选参数分布中对两种模型类型的辅助参数进行建模的重要性。

相似文献

1
Estimating and modeling the cure fraction in population-based cancer survival analysis.基于人群的癌症生存分析中治愈分数的估计与建模。
Biostatistics. 2007 Jul;8(3):576-94. doi: 10.1093/biostatistics/kxl030. Epub 2006 Oct 4.
2
Cure fraction estimation from the mixture cure models for grouped survival data.基于分组生存数据的混合治愈模型的治愈分数估计
Stat Med. 2004 Jun 15;23(11):1733-47. doi: 10.1002/sim.1774.
3
CANSURV: A Windows program for population-based cancer survival analysis.CANSURV:一款用于基于人群的癌症生存分析的Windows程序。
Comput Methods Programs Biomed. 2005 Dec;80(3):195-203. doi: 10.1016/j.cmpb.2005.08.002. Epub 2005 Oct 27.
4
Improved survival time: what can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer?生存时间的改善:生存治愈模型能告诉我们关于晚期结直肠癌、卵巢癌和睾丸癌基于人群的生存改善情况有哪些?
Cancer. 2008 May 15;112(10):2289-300. doi: 10.1002/cncr.23425.
5
A SAS macro for parametric and semiparametric mixture cure models.用于参数和半参数混合治愈模型的SAS宏。
Comput Methods Programs Biomed. 2007 Feb;85(2):173-80. doi: 10.1016/j.cmpb.2006.10.008. Epub 2006 Dec 8.
6
Estimating the proportion cured of cancer: some practical advice for users.估算癌症治愈比例:用户实用建议。
Cancer Epidemiol. 2013 Dec;37(6):836-42. doi: 10.1016/j.canep.2013.08.014. Epub 2013 Sep 14.
7
A relative survival regression model using B-spline functions to model non-proportional hazards.一种使用B样条函数对非比例风险进行建模的相对生存回归模型。
Stat Med. 2003 Sep 15;22(17):2767-84. doi: 10.1002/sim.1484.
8
Parametric mixture model for analysing relative survival of patients with multiple cancers.
J Cancer Epidemiol Prev. 2002;7(3):147-53.
9
The cure of cancer: a European perspective.癌症的治疗:欧洲视角
Eur J Cancer. 2009 Apr;45(6):1067-79. doi: 10.1016/j.ejca.2008.11.034. Epub 2009 Jan 7.
10
Flexible parametric models for relative survival, with application in coronary heart disease.用于相对生存的灵活参数模型及其在冠心病中的应用。
Stat Med. 2007 Dec 30;26(30):5486-98. doi: 10.1002/sim.3064.

引用本文的文献

1
Unlocking Asthma Remission: Key Insights From an Expert Roundtable Discussion.开启哮喘缓解之路:专家圆桌讨论的关键见解
Respirology. 2025 Jun;30(6):466-479. doi: 10.1111/resp.70047. Epub 2025 May 23.
2
Analysis of temporal survival trends: considerations and best practice.时间生存趋势分析:注意事项与最佳实践
BMC Med Res Methodol. 2025 Feb 22;25(1):51. doi: 10.1186/s12874-025-02505-5.
3
Cost-Effectiveness of Nivolumab Plus Ipilimumab versus Chemotherapy for Previously Untreated Metastatic NSCLC Using Mixture-Cure Survival Analysis Based on CheckMate 227 5-Year Data.
基于CheckMate 227 5年数据,使用混合治愈生存分析评估纳武利尤单抗联合伊匹木单抗与化疗用于既往未治疗的转移性非小细胞肺癌的成本效益
Pharmacoecon Open. 2025 Mar;9(2):247-257. doi: 10.1007/s41669-024-00545-z. Epub 2024 Dec 6.
4
Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials.评估 III/IV 期黑色素瘤切除患者的长期生存率:来自 CheckMate 238 和欧洲癌症研究与治疗组织 18071 试验的分析
J Clin Oncol. 2025 Mar 10;43(8):929-937. doi: 10.1200/JCO.24.00237. Epub 2024 Oct 8.
5
Evidence of being cured for nasopharyngeal carcinoma: results of a multicenter patient-based study in China.鼻咽癌治愈证据:一项基于中国患者的多中心研究结果
Lancet Reg Health West Pac. 2024 Jul 19;49:101147. doi: 10.1016/j.lanwpc.2024.101147. eCollection 2024 Aug.
6
: An End-to-End Pipeline for Implementing Mixture Cure Models With an Application to Liposarcoma Data.: 一个用于实现混合治愈模型的端到端管道,应用于脂肪肉瘤数据。
JCO Clin Cancer Inform. 2024 Aug;8:e2300234. doi: 10.1200/CCI.23.00234.
7
Mixture and Non-mixture Cure Models for Health Technology Assessment: What You Need to Know.用于卫生技术评估的混合与非混合治愈模型:你需要了解的内容。
Pharmacoeconomics. 2024 Oct;42(10):1073-1090. doi: 10.1007/s40273-024-01406-7. Epub 2024 Jul 5.
8
A generalized Gompertz promotion time cure model and its fitness to cancer data.一种广义的冈珀茨促癌时间治愈模型及其对癌症数据的拟合
Heliyon. 2024 Jun 1;10(11):e32038. doi: 10.1016/j.heliyon.2024.e32038. eCollection 2024 Jun 15.
9
Cost-utility analysis of second-line axicabtagene ciloleucel versus standard of care in Japan based on the ZUMA-7 trial.基于 ZUMA-7 试验的二线 axicabtagene ciloleucel 与标准治疗的日本成本-效用分析。
Future Oncol. 2024;20(30):2279-2291. doi: 10.1080/14796694.2024.2351353. Epub 2024 Jun 5.
10
Updated cost-effectiveness analysis of adebrelimab plus chemotherapy for extensive-stage small cell lung cancer in China.中国广泛期小细胞肺癌阿得贝利单抗联合化疗的更新成本效益分析。
BMJ Open. 2024 Apr 5;14(4):e077090. doi: 10.1136/bmjopen-2023-077090.